Document is current
Any future updates will be listed below
-
Authors
George, Benson M.
Eleftheriou, Maria
Yankova, Eliza https://orcid.org/0000-0003-2913-0012
Perr, Jonathan
Chai, Peiyuan
Nestola, Gianluca
Almahayni, Karim https://orcid.org/0000-0001-6844-4327
Evans, Siân
Damaskou, Aristi
Hemberger, Helena
Lebedenko, Charlotta G.
Rak, Justyna
Yu, Qi
Bapcum, Ece
Russell, James
Bagri, Jaana
Volk, Regan F. https://orcid.org/0000-0001-6748-719X
Spiekermann, Malte
Stone, Richard M.
Giotopoulos, George
Huntly, Brian J. P. https://orcid.org/0000-0003-0312-161X
Baxter, Joanna
Camargo, Fernando
Liu, Jie
Zaro, Balyn W. https://orcid.org/0000-0002-8938-9889
Vassiliou, George S. https://orcid.org/0000-0003-4337-8022
Möckl, Leonhard https://orcid.org/0000-0003-1387-886X
de la Rosa, Jorge
Flynn, Ryan A. https://orcid.org/0000-0001-5013-0442
Tzelepis, Konstantinos https://orcid.org/0000-0002-4865-7648
-
Funding
Funding for this research was provided by:
Sontag Foundation
Damon Runyon Cancer Research Foundation (#74-23)
Burroughs Wellcome Fund
Max-Planck-Gesellschaft
Wellcome Trust (RG94424, RG106133, RG83195)
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 20 March 2025
First Online: 23 April 2025
Competing interests
: R.A.F. is a stockholder of Orna Therapeutics and is a board of director member and stockholder of Chronus Health and Blue Planet Systems. K.T. has received stock options and research funding from Storm Therapeutics. J.d.l.R. is an employee of Altos Labs. G.S.V. is a consultant to STRM.BIO and holds a research grant from AstraZeneca for research unrelated to that presented here. R.A.F., K.T. and B.M.G. have filed a patent on the sequences and use of mAb2 in the context of cancer therapeutics and are cofounders of a company pursuing commercialization. The other authors declare no competing interests.
